AnnJi Pharmaceutical überführt AJ201 in die zulassungsrelevante Phase-3-Studie „ROMA-KD" zur Behandlung der spinalen und bulbären Muskelatrophie (SBMA)

Phase 3AJ201Positive

AI Analysis

Summary

AnnJi Pharmaceutical advanced AJ201 (Rosolutamid) into Phase 3 registration-relevant study "ROMA-KD" for treatment of spinal and bulbar muscular atrophy (SBMA). AJ201 is described as the only known investigational therapy in clinical Phase 3 development for this indication.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

0.60

Phase 3SBMARosolutamidClinical trial advancementRare disease

Read the original article

Published by PR Newswire Clinical Trials on October 6, 2026 1:51 AM

Read Original